Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento

Detalhes bibliográficos
Autor(a) principal: Valle, José Carlos do
Data de Publicação: 2023
Outros Autores: Atalécio, Luiz Eduardo, Rezende, Magda Cortês, Silveira, Luiz Antonio, Soares, João Luiz Campos
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3280
Resumo: Eigthy-six patients with breast cancer and positive axilar limphonodes were subrnitted to a modified radical mastectomy and adjuvant treatment with cyclophosphamyde 600mg/m2, 5-fluouracil 600mg/m2 and methotrexate 40mg/m2 by intravenous route, repetead each 21 days, during six months (eight cycles) (CMF-mod). The CMFmod was started irnmediately after surgery. The results were compared with 186 patients from the same institution (historical controls) treated by Halsted mastectorny and irradiation. At 48 months folllow-up, 72 patients (85%) in the CMFmod treated group were alive with 42 (49%) free of disease. In the control group, 132 (71%) were alive with 94 (51%) free of disease (p=0.70 andp <0.25, NS). There was a trend favoring the CMF treated premenopause woman with 1 to 3 N+: overall survival (SV): 26/26 (100%) and relapse free survival (RFS): 21/26 (81%) when cornpared to controls: SV: 36/44 (83%) and RFS: 30/44 (68%) (p <0. 15 and p <a 80, NS). We conclude that it may be necessary a longer follow-up to confirm the results obtained by Bonadonna.
id INCA-1_32de8c6961f45d6035731bc8c5466570
oai_identifier_str oai:rbc.inca.gov.br:article/3280
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimentoCâncer da MamaQuimioterapiaSobrevidaBreast CancerChemotherepySurvivalEigthy-six patients with breast cancer and positive axilar limphonodes were subrnitted to a modified radical mastectomy and adjuvant treatment with cyclophosphamyde 600mg/m2, 5-fluouracil 600mg/m2 and methotrexate 40mg/m2 by intravenous route, repetead each 21 days, during six months (eight cycles) (CMF-mod). The CMFmod was started irnmediately after surgery. The results were compared with 186 patients from the same institution (historical controls) treated by Halsted mastectorny and irradiation. At 48 months folllow-up, 72 patients (85%) in the CMFmod treated group were alive with 42 (49%) free of disease. In the control group, 132 (71%) were alive with 94 (51%) free of disease (p=0.70 andp <0.25, NS). There was a trend favoring the CMF treated premenopause woman with 1 to 3 N+: overall survival (SV): 26/26 (100%) and relapse free survival (RFS): 21/26 (81%) when cornpared to controls: SV: 36/44 (83%) and RFS: 30/44 (68%) (p <0. 15 and p <a 80, NS). We conclude that it may be necessary a longer follow-up to confirm the results obtained by Bonadonna.Oitenta e seis pacientes com câncer de mama e linfonodos axilares positivos foram submetidos à mastectomia radical modificada seguida de quimioterapia com ciclo fosfamida e fluorouracil na dose de 600mg/m2 e methotrexate 40mg/m2, endovenosos, repetidos a cada 21 dias (CMFmod), durante seis meses (Oito ciclos). O tratamento adjuvante era iniciado no prazo máximo de 30 dias da cirurgia. O resultado do CMFmod foi comparado com grupo-controle histórico da própria instituição, constituída por 186 doentes tratadas pela mastectomia radical à Halsted e radioterapia. Decorridos 48 meses de seguimento, 72 (85%) estavam vivas e 42 (49/c) livres de doença no grupo do CMFmod e no grupo-controle 132 (7 1%) estavam vivas com 94 (51%) sem evidência de doença (p = 0,70 e p <0,25, NS). Há uma tendência para o CMFmod beneficiar as mulheres da pré-menopausa com 1 a 3 N+: sobrevida global (SV) 26/26 (10070) e intervalo livre de doença (ILD) = 21/26 (81%) quando comparado com o controle - SV: 36/44 (83%) e ILD 9 - 30/44 (68%) (p <0,15 e p <0,80, NS). Contudo, é necessário observação mais prolongada para possível ratificação dos resultados benéficos obtidos por Bonadonna com o CMF clássico com seis meses.INCA2023-08-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/328010.32635/2176-9745.RBC.1986v32n4.3280Revista Brasileira de Cancerologia; Vol. 32 No. 4 (1986): Dec.; 287-295Revista Brasileira de Cancerologia; Vol. 32 Núm. 4 (1986): dic.; 287-295Revista Brasileira de Cancerologia; v. 32 n. 4 (1986): dez.; 287-2952176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/3280/2128https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessValle, José Carlos doAtalécio, Luiz EduardoRezende, Magda CortêsSilveira, Luiz AntonioSoares, João Luiz Campos2023-08-07T16:28:39Zoai:rbc.inca.gov.br:article/3280Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2023-08-07T16:28:39Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
title Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
spellingShingle Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
Valle, José Carlos do
Câncer da Mama
Quimioterapia
Sobrevida
Breast Cancer
Chemotherepy
Survival
title_short Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
title_full Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
title_fullStr Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
title_full_unstemmed Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
title_sort Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
author Valle, José Carlos do
author_facet Valle, José Carlos do
Atalécio, Luiz Eduardo
Rezende, Magda Cortês
Silveira, Luiz Antonio
Soares, João Luiz Campos
author_role author
author2 Atalécio, Luiz Eduardo
Rezende, Magda Cortês
Silveira, Luiz Antonio
Soares, João Luiz Campos
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Valle, José Carlos do
Atalécio, Luiz Eduardo
Rezende, Magda Cortês
Silveira, Luiz Antonio
Soares, João Luiz Campos
dc.subject.por.fl_str_mv Câncer da Mama
Quimioterapia
Sobrevida
Breast Cancer
Chemotherepy
Survival
topic Câncer da Mama
Quimioterapia
Sobrevida
Breast Cancer
Chemotherepy
Survival
description Eigthy-six patients with breast cancer and positive axilar limphonodes were subrnitted to a modified radical mastectomy and adjuvant treatment with cyclophosphamyde 600mg/m2, 5-fluouracil 600mg/m2 and methotrexate 40mg/m2 by intravenous route, repetead each 21 days, during six months (eight cycles) (CMF-mod). The CMFmod was started irnmediately after surgery. The results were compared with 186 patients from the same institution (historical controls) treated by Halsted mastectorny and irradiation. At 48 months folllow-up, 72 patients (85%) in the CMFmod treated group were alive with 42 (49%) free of disease. In the control group, 132 (71%) were alive with 94 (51%) free of disease (p=0.70 andp <0.25, NS). There was a trend favoring the CMF treated premenopause woman with 1 to 3 N+: overall survival (SV): 26/26 (100%) and relapse free survival (RFS): 21/26 (81%) when cornpared to controls: SV: 36/44 (83%) and RFS: 30/44 (68%) (p <0. 15 and p <a 80, NS). We conclude that it may be necessary a longer follow-up to confirm the results obtained by Bonadonna.
publishDate 2023
dc.date.none.fl_str_mv 2023-08-07
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/3280
10.32635/2176-9745.RBC.1986v32n4.3280
url https://rbc.inca.gov.br/index.php/revista/article/view/3280
identifier_str_mv 10.32635/2176-9745.RBC.1986v32n4.3280
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/3280/2128
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 32 No. 4 (1986): Dec.; 287-295
Revista Brasileira de Cancerologia; Vol. 32 Núm. 4 (1986): dic.; 287-295
Revista Brasileira de Cancerologia; v. 32 n. 4 (1986): dez.; 287-295
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042234884882432

Registros relacionados